Exousia Bio, Inc. (OTCPK: LMMY)
Health Care · Biotechnology · US
$0.16
-59.62% today · -38.5% 1Y
Exousia Bio, Inc. (OTCPK: LMMY) operates in the Biotechnology industry within the Health Care sector. The company is valued at $8.48M and employs 2 people.
Over the last twelve months the share price has lost 38.5%, trading between 0.12 and 0.94.
Tweenvest scores Exousia Bio, Inc. across four factors: quality 24/100. Its strongest factor is quality.
LMMY price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $8.48M
- Revenue (TTM)
- $0.00
- P/E
- —
- EPS
- -0.01
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $0.94
- 52-week low
- $0.12
- Avg volume (3M)
- —
- Shares outstanding
- 52.50M
- Employees
- 2
- Next earnings
- —
About Exousia Bio, Inc.
Exousia Bio, Inc. is a biotechnology company that designs, develops, and manufactures mammalian- and plant-derived exosomes using proprietary technologies for nucleic acid loading and targeted delivery to tissues and cells. The company's platform enables the custom production of exosomes with enhanced genetic functionality that can selectively target specific cells to address diseases. The company was formerly known as LAMY and changed its name to Exousia Bio, Inc. in January 2026.
- Founded
- 2022
- Listed since
- Oct 1, 2024
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.